Literature DB >> 701262

Characterization of intermediate hemoglobin produced during methemoglobin reduction by ascorbic acid.

A Tomoda, M Takeshita, Y Yoneyama.   

Abstract

Methemoglobin reduction by ascorbic acid was found apparently to cease halfway without further reduction. Studies by isoelectric focusing on Ampholine plate gel revealed that the solutions of the halfway reduced methemoglobin are composed of about 6% oxyhemoglobin, 59% intermediate hemoglobin, and 35% methemoglobin. The intermediate hemoglobin was isolated by CM Sephadex C-50 column chromatography and identified as alpha3+beta2+ valency hybrid by studies using the pattern of isoelectric focusing of p-chloromercuribenzoate-treated intermediate hemoglobin on Ampholine plate gel, absorption spectra, and difference spectra induced by the addition of inositol hexaphosphate in comparison with the reconstituted valency hybrids, alpha3+beta2+ and alpha2+beta3+. Essentially no alpha2+beta3+ valency hybrid was included in the intermediate hemoglobin solutions. These results suggest that methemoglobin reduction by ascorbic acid is mainly initiated by the attack of beta-methemoglobin chains accompanied by the following scheme. Methemoglobin leads to alpha3+beta2+ valency hybrid leads to oxyhemoglobin. The course of methemoglobin reduction by ascorbic acid through alpha2+beta3+ is likely to be small.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 701262

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Quaternary structure dynamics and carbon monoxide binding kinetics of hemoglobin valency hybrids.

Authors:  J S Philo; U Dreyer; J W Lary
Journal:  Biophys J       Date:  1996-04       Impact factor: 4.033

2.  A stopped-flow study of the cupric ion oxidation of adult-human haemoglobin.

Authors:  T Brittain
Journal:  Biochem J       Date:  1980-06-01       Impact factor: 3.857

3.  Changes in intermediate haemoglobins during methaemoglobin reduction by NADPH-flavin reductase.

Authors:  A Tomoda; T Yubisui; A Tsuji; Y Yoneyama
Journal:  Biochem J       Date:  1979-04-01       Impact factor: 3.857

4.  Analyis of met-form haemoglobins in human erythrocytes of normal adults and of a patient with hereditary methaemoglobinaemia due to deficiency of NADH-cytochrome b5 reductase.

Authors:  A Tomoda; M Imoto; M Hirano; Y Yoneyama
Journal:  Biochem J       Date:  1979-08-01       Impact factor: 3.857

5.  Involvement of oxidoreductive reactions of intracellular haemoglobin in the metabolism of 3-hydroxyanthranilic acid in human erythrocytes.

Authors:  A Tomoda; E Shirasawa; S Nagao; M Minami; Y Yoneyama
Journal:  Biochem J       Date:  1984-09-15       Impact factor: 3.857

6.  Changes in intermediate haemoglobins during autoxidation of haemoglobin.

Authors:  A Tomoda; Y Yoneyama; A Tsuji
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

7.  Organotin-protein interactions. Binding of triethyltin bromide to cat haemoglobin.

Authors:  K R Siebenlist; F Taketa
Journal:  Biochem J       Date:  1986-01-15       Impact factor: 3.857

8.  Mechanism of methaemoglobin reduction by human erythrocytes.

Authors:  A Tomoda; M Ida; A Tsuji; Y Yoneyama
Journal:  Biochem J       Date:  1980-05-15       Impact factor: 3.857

9.  Oxidative and reductive reactions of sulphhaemoglobin with various reagents correlated with changes in quaternary structure of the protein.

Authors:  A Tomoda; A Kakizuka; Y Yoneyama
Journal:  Biochem J       Date:  1984-08-01       Impact factor: 3.857

10.  Comparison of the oxidative reactivity of recombinant fetal and adult human hemoglobin: implications for the design of hemoglobin-based oxygen carriers.

Authors:  Michelle Simons; Svetlana Gretton; Gary G A Silkstone; Badri S Rajagopal; Victoria Allen-Baume; Natalie Syrett; Thoufieq Shaik; Nelida Leiva-Eriksson; Luca Ronda; Andrea Mozzarelli; Michael B Strader; Abdu I Alayash; Brandon J Reeder; Chris E Cooper
Journal:  Biosci Rep       Date:  2018-07-02       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.